A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia
Authors: Sun, J.; Xiang, H.; Yang, L.-L.; Chen, J.-B.
Source: Current Medicinal Chemistry, Volume 18, Number 23, August 2011 , pp. 3576-3589(14)
Publisher: Bentham Science Publishers
Abstract:Benign prostatic hyperplasia (BPH) is a kind of common noncancerous prostate gland enlargement with growing tendency in recent years. 5α-reductase is the key enzyme responsible for dihydrotestosterone biosynthesis and has been considered as an important target for designing inhibitors as potent therapeutic agents for BPH. Finasteride, the first steroidal 5α-reductase inhibitor, has been marketed worldwide as a drug for BPH. During these years, many other novel types of 5α-reductase inhibitors are being studied. This review summarizes recent advancement in steroidal 5α-reductase inhibitors.
Document Type: Research Article
Publication date: August 2011
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.